Kenvue's Q4 print, derived from the 10-K filed February 20, 2026, covering the fiscal year ended December 28, 2025, delivered a modest EPS beat against consensus but offered no structural vindication of the narratives circulating around the stock. The headline numbers landed slightly above expectations, yet the full-year revenue of $15.124 billion and an operating margin of 15.96% tell a story of a business operating under compression — one where incremental beats are occurring against a backdrop of lowered guidance, a pending acquisition that reshapes the investment thesis entirely, and a valuation that has drifted well above what the underlying fundamentals support.
The Result
On an adjusted basis, Q4 EPS came in at $0.27 against a consensus estimate of $0.22, representing a +22.7% beat on the earnings line. Revenue for the period registered at $3.78 billion against estimates, producing a negligible +0.02% revenue surprise — a print that technically cleared the bar but offered no meaningful topline acceleration. The SEC-filed full-year EPS of $0.76 and annual revenue of $15.124 billion provide the foundational reference against which all forward claims must be measured.
Print Scorecard
| Metric | Actual | Estimate | Surprise % | Source |
| Q4 EPS (adjusted) | $0.27 | $0.22 | +22.7% | 10-K filed 2026-02-20 / Benzinga estimates |
|---|---|---|---|---|
| Q4 Revenue | $3.78B | — | +0.02% | 10-K filed 2026-02-20 / Benzinga estimates |
| Full-Year EPS (SEC) | $0.76 | — | — | 10-K filed 2026-02-20, period ended 2025-12-28 |
| Full-Year Revenue | $15.124B | — | — | 10-K filed 2026-02-20, period ended 2025-12-28 |
| Gross Margin | 58.13% | — | — | 10-K filed 2026-02-20 |
| Operating Margin | 15.96% | — | — | 10-K filed 2026-02-20 |
| Net Margin | 9.72% | — | — | 10-K filed 2026-02-20 |
The EPS beat is statistically material; the revenue surprise is not.
Narrative Test
The prevailing narrative entering this print positioned Kenvue as a defensive consumer staples asset benefiting from Q1 earnings momentum and the transformative optionality of a pending Kimberly-Clark acquisition. Headlines from Reuters, Zacks, and MarketBeat amplified that framing, presenting the stock as both a near-term earnings compounder and a safe harbor during market volatility. The 24/7 Wall St. inclusion of KVUE in a dividend income portfolio further cemented the safety-and-yield thesis in circulation.
The print complicates that narrative without fully breaking it. The EPS beat is real — $0.27 against $0.22 is a 22.7% positive deviation — and Q1 headlines confirming beats provided pre-print momentum. However, the revenue surprise of +0.02% is, for practical purposes, a flat result, and the reduced guidance issued by management directly contradicts the growth component of the safety story. A company trading at a trailing P/E of 21.1x with a 52-week return of -27.5% and a net margin of 9.72% does not present the risk-adjusted profile the media framing implies. The forensic rebuttal is straightforward: the earnings beat was narrow and driven by cost management rather than revenue acceleration, the guidance reduction signals limited near-term topline visibility, and the stock's estimated fair value gap of +19.81% indicates the market has already partially re-rated the name — yet not fully. The narrative is not broken, but it is exhausted. The Kimberly-Clark acquisition thesis is now doing the primary load-bearing work for any bullish case.
Forensic Dissection
Gross margin of 58.13% reflects the premium positioning of Kenvue's portfolio — brands including Tylenol, Neutrogena, and Listerine carry inherent pricing power. That figure is structurally solid for a consumer health business and suggests limited near-term deterioration in product mix or input cost pressure at the gross line.
The compression becomes visible at the operating level. An operating margin of 15.96% against a 58.13% gross margin implies a selling, general, and administrative cost load that consumes roughly 42 percentage points of gross profit before arriving at operating income. That spread warrants scrutiny: post-spinoff from Johnson & Johnson, Kenvue has been building out standalone infrastructure, and the SG&A burden of operating independently at scale has not fully rationalized. The net margin of 9.72% — approximately 617 basis points below operating margin — reflects interest expense on the balance sheet inherited from the separation, a structural drag that will not resolve quickly absent either debt paydown or a transaction that alters the capital structure.
The pending Kimberly-Clark transaction introduces a material contingency that conventional margin analysis cannot fully capture. If consummated, the combined entity's cost structure, revenue mix, and capital allocation priorities will shift significantly. Until transaction terms, financing mechanics, and regulatory timelines are disclosed with greater precision, treating current margin levels as a durable baseline carries analytical risk.
The Q4 revenue of $3.78 billion, while marginally above estimates, implies an annualized run rate consistent with the full-year $15.124 billion figure — meaning no meaningful sequential reacceleration occurred in the back half of fiscal 2025. Volume versus price mix decomposition from the 10-K would clarify whether the gross margin hold was driven by volume or pricing; that distinction matters for assessing sustainability.
Watchlist — Four Items for the Next Quarter and 30 Days
- Transaction disclosure on the Kimberly-Clark deal: financing structure, regulatory filing dates, and any announced synergy targets will be the single largest re-rating catalyst in either direction.
- Guidance revision trajectory: management already lowered its outlook; the next formal guidance update will confirm whether the reduction was a one-time recalibration or the leading edge of a sustained downward revision cycle.
- SG&A as a percentage of revenue: any evidence of post-spinoff cost rationalization would support operating margin recovery; failure to show leverage at current revenue levels signals structural overhang.
- Short interest at 3.64% of float: not extreme, but directionally worth monitoring as the acquisition timeline clarifies — both squeeze potential and incremental short accumulation are live scenarios.
The Q4 print confirms that Kenvue's investment case now rests primarily on transaction optionality rather than organic fundamental momentum, and that divergence — between a narrative of defensive stability and a reality of margin compression, flat topline growth, and reduced guidance — represents the core structural tension the market has yet to fully resolve.